patent.fyi
Applications  /  US 2026/0355122
United States Patent Application Publication

US 2026/0355122 A1

Published
Nov 12, 2026
Filed
Jun 12, 2026
Earliest date on the face
Dec 19, 2023
Classification
A61K 9/5146
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Quaternary ammonium binds RNA

What ifWhat if a permanently charged quaternary ammonium lipid binds the RNA?
Claim language“C12-200 ionizable cationic lipid”

A dioleoyl lipid with a trimethylammonium headgroup carries a positive charge across the formulation pH range. Its headgroup associates with RNA phosphates, while its hydrocarbon chains pack with the other lipids.

1.1Phosphatidylcholine supports particle packing

What ifWhat if a saturated phosphatidylcholine serves as the helper phospholipid?
Claim language“1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE)”

Distearoyl phosphatidylcholine has two saturated 18-carbon chains that pack with the hydrophobic chains of neighboring lipids. Its hydrated phosphocholine headgroup helps stabilize lipid regions in contact with water.

1.1Polysarcosine forms the surface layer

What ifWhat if a lipid-linked polysarcosine chain forms the hydrated surface layer?
Claim language“and (1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt)) (DMPE-PEG)”

A lipid anchor inserts into the particle, and the attached polysarcosine chain extends into the surrounding water. Compression and overlap of these hydrated chains resist close contact between particles.

1.1Sodium supplies the counterion

What ifWhat if the same conjugated phospholipid enters formulation as its sodium salt?
Claim language“(ammonium salt)) (DMPE-PEG)”

Sodium balances the negative charge on the phospholipid in the starting material. After aqueous dispersion, the dimyristoyl chains anchor the conjugate in the particle and the polyethylene glycol chain extends into the surrounding water.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Reference dispersion for instrument training

A training laboratory uses a cargo-free dispersion containing C12-200, DOPE, cholesterol, and DMPE-PEG as a sample for dynamic light scattering. A sealed cuvette holds the dispersion, and a matched cuvette holds the buffer blank. Trainees collect replicate measurements and compare the reported hydrodynamic diameter and polydispersity across cuvette positions.

Component substitution

Saturated phospholipid in a reference dispersion

Distearoylphosphatidylcholine replaces DOPE in a cargo-free dispersion containing C12-200, cholesterol, and DMPE-PEG. Its two saturated C18 chains replace the two monounsaturated chains of DOPE. Differential scanning calorimetry records the heat flow of the hydrated dispersion during heating to characterize its thermal transitions.

Parameter or scale variation

Three fill volumes for stability measurements

A single cargo-free batch containing C12-200, DOPE, cholesterol, and DMPE-PEG is split into 0.5, 1.0, and 1.5 mL fills in identical 2 mL glass vials. The same vial and closure geometry produces three different headspace volumes. Sealed replicate vials are held at 4 °C, and separate vials are opened for particle-size measurements on days 0, 7, and 28.

Combination with existing systems

Chromatographic separation with inline light scattering

A size-exclusion chromatography system receives a cargo-free dispersion containing C12-200, DOPE, cholesterol, and DMPE-PEG through a fixed-volume sample loop. The column outlet feeds a multi-angle light scattering detector, followed by a fraction collector. The detector records scattering intensity across the elution profile, and the collector retains early and late fractions for separate particle-size measurements.

Temperature cycling with optical transmission monitoring

A sealed optical cuvette holds a cargo-free dispersion containing C12-200, DOPE, cholesterol, and DMPE-PEG. A temperature-controlled spectrophotometer changes the cuvette temperature while measuring transmitted light at a fixed visible wavelength. A matched buffer blank provides the baseline, and the resulting transmission trace shows when the dispersion becomes more or less turbid during the cycle.

Automated or data-driven variant

Automated review of replicate scattering measurements

A particle-sizing instrument exports replicate measurements from cargo-free dispersions containing C12-200, DOPE, cholesterol, and DMPE-PEG. Software groups measurements by sample identifier and calculates the median hydrodynamic diameter and the range of polydispersity values for each group. The script flags groups with missing replicates or instrument error codes and writes the measurements and flags to a review table.

Specific version of a part

Defined four lipid proportions

The ionizable lipid, dioleoyl phosphatidylethanolamine, cholesterol, and polyethylene glycol conjugate account for 50, 10, 38.5, and 1.5 mole percent of total lipid, respectively. The mole fractions describe the lipid feed before particle assembly.

Ethanol stock for lipid assembly

A single ethanol stock contains the ionizable lipid, dioleoyl phosphatidylethanolamine, cholesterol, and the ammonium salt of the dimyristoyl phospholipid conjugate. Mixing the stock with an aqueous phase lowers the ethanol concentration and drives the lipids to assemble into particles.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2022/0047723 A1
Published
Feb 17, 2022
Filed
Nov 26, 2019
Class
A61K 48/0025
Document BUS 11,337,923 B2
Published
May 24, 2022
Filed
Apr 11, 2019
Class
A61K 9/1271
Claim 1
Document A
Document B
1.1C12-200 ionizable cationic lipid, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), cholesterol, and (1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt)) (DMPE-PEG).
In some particular embodiments, the smLNP compositions described herein include the following lipids: a C12-200 amino lipid; a 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE); a cholesterol; and a PEG-DMPE.
A · US 2022/0047723 A1 · ¶ 88
The nanoliposome may include lecithin (α-phosphatidylcholine), a cationic phospholipid and cholesterol, thereby forming a membrane that constitutes a nanoliposome from the lecithin, cationic phospholipid and cholesterol.
B · US 11,337,923 B2 · ¶ 39

An empty cell means only that no passage was reproduced there.

Statements in these documents
However, the delivery of large biologically active agents, such as site-specific endonucleases or nucleic acids encoding the same, to target cells or tissues is often hindered by difficulties in the agents reaching the target living cell or tissue.
A · US 2022/0047723 A1 · ¶ 5
In some embodiments, the disclosure provides methods for treating a disease using the compositions and/or methods described herein.
A · US 2022/0047723 A1 · ¶ 8
However, side effects such as loss of libido, erectile dysfunction, etc. occur in patients who take such a drug, and hair loss resumes when administration of the drug is discontinued.
B · US 11,337,923 B2 · ¶ 5
Thereby, a carrier having good drug delivery efficiency into the dermis is manufactured and used as a composition for alleviating or treating hair loss, thus culminating in the present invention.
B · US 11,337,923 B2 · ¶ 8
Cite aspatent.fyi, US 2026/0355122 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355122/, SHA-256 cc824c50d5ffb30c42529a64d774c08b6fb55d86e8e6b3c2409b1c411484361d
First published
Permanent addresshttps://patent.fyi/US20260355122/
Content fingerprint (SHA-256)cc824c50d5ffb30c42529a64d774c08b6fb55d86e8e6b3c2409b1c411484361d
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi